These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19715753)

  • 41. Endothelial dysfunction: Pathophysiology and therapeutic targets for sepsis-induced multiple organ dysfunction syndrome.
    Tang F; Zhao XL; Xu LY; Zhang JN; Ao H; Peng C
    Biomed Pharmacother; 2024 Sep; 178():117180. PubMed ID: 39068853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Protective effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced acute kidney injury in a rat model of sepsis.
    Liu L; Song Y; Zhao M; Yi Z; Zeng Q
    Int Urol Nephrol; 2015 Oct; 47(10):1745-52. PubMed ID: 26300162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mitochondrial function in sepsis.
    Jeger V; Djafarzadeh S; Jakob SM; Takala J
    Eur J Clin Invest; 2013 May; 43(5):532-42. PubMed ID: 23496374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bench-to-bedside review: Targeting antioxidants to mitochondria in sepsis.
    Galley HF
    Crit Care; 2010; 14(4):230. PubMed ID: 20804578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mitochondrial quality control mechanisms as potential therapeutic targets in sepsis-induced multiple organ failure.
    Wu Y; Yao YM; Lu ZQ
    J Mol Med (Berl); 2019 Apr; 97(4):451-462. PubMed ID: 30788535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Classical corticosteroids and new lipid peroxidation inhibitors in the therapy of multiple organ failure (MOF).
    Chiara O; Padalino P; Fattori L; Ravizzini C; Turconi MG; Tiberio G
    Minerva Chir; 1997 Sep; 52(9):1095-102. PubMed ID: 9401356
    [No Abstract]   [Full Text] [Related]  

  • 47. Sepsis and multiple organ dysfunction syndrome: a clinical-mechanistic overview.
    Livingston DH; Mosenthal AC; Deitch EA
    New Horiz; 1995 May; 3(2):257-66. PubMed ID: 7583167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome.
    Crouser ED
    Mitochondrion; 2004 Sep; 4(5-6):729-41. PubMed ID: 16120428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Study on delay two-phase multiple organ dysfunction syndrome.
    Hu S; Sheng Z; Zhou B; Guo Z; Lu J; Xue L; Jin H; Sun X; Sun S; Li J; Lü Y
    Chin Med J (Engl); 1998 Feb; 111(2):101-8. PubMed ID: 10374366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protecting the permeability pore and mitochondrial biogenesis.
    Piantadosi CA; Carraway MS; Haden DW; Suliman HB
    Novartis Found Symp; 2007; 280():266-76; discussion 276-80. PubMed ID: 17380800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Organ dysfunction in patients with severe sepsis.
    Vincent JL
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S69-72. PubMed ID: 16895511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential role of reactive oxygen species in pancreatitis-associated multiple organ dysfunction.
    Shi C; Andersson R; Zhao X; Wang X
    Pancreatology; 2005; 5(4-5):492-500. PubMed ID: 16020935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome.
    Wang H; Ma S
    Am J Emerg Med; 2008 Jul; 26(6):711-5. PubMed ID: 18606328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure.
    Singer M
    Virulence; 2014 Jan; 5(1):66-72. PubMed ID: 24185508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure.
    Protti A; Singer M
    Crit Care; 2006; 10(5):228. PubMed ID: 16953900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome.
    Flierl MA; Schreiber H; Huber-Lang MS
    J Invest Surg; 2006; 19(4):255-65. PubMed ID: 16835140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmaconutrition with parenteral selenium in sepsis].
    Langlois PL; de Oliveira Figliolino LF; Hardy G; Manzanares W
    Med Intensiva; 2014 Apr; 38(3):173-80. PubMed ID: 24021703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oxidants and antioxidant therapy.
    Rotstein OD
    Crit Care Clin; 2001 Jan; 17(1):239-47. PubMed ID: 11219232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms and treatment of organ failure in sepsis.
    Lelubre C; Vincent JL
    Nat Rev Nephrol; 2018 Jul; 14(7):417-427. PubMed ID: 29691495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Derangements in mitochondrial metabolism in intercostal and leg muscle of critically ill patients with sepsis-induced multiple organ failure.
    Fredriksson K; Hammarqvist F; Strigård K; Hultenby K; Ljungqvist O; Wernerman J; Rooyackers O
    Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1044-50. PubMed ID: 16803854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.